NYXH · Categories · Earnings
NYXH - Earnings announcements
Nyxoah SA (NYXH) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for NYXH
- Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of SalesFoundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025. Recent Financial and Operating Highlights Fourth quarter gross revenue of €6
- Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or
- Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U.S. Commercialization Mont-Saint-Guibert, Belgium – January 12, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited fourth quarter and full year 2025 financial and operating results. Preliminary, Unaudited Fourth Quarter and Full Year 2025 R
- Nyxoah Reports Third Quarter 2025 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2025. Recent Financial and Operating Highlights Completed the first commercial implants of U.S. patients, and genera
- Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through t
- Nyxoah Reports Second Quarter Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hyp
- Nyxoah Announces Preliminary Results for the Second Quarter of 2025Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates. Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to sever
- Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyx
- Nyxoah Reports First Quarter Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the first quarter of 2025. Recent Financial and Operating Highlights Received an FDA Approvable Letter indicating the FDA wil
- Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's
- Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsFDA PMA Application Review Nearing ConclusionPositioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024. Recent Financial and Operating Highlights Revenue for the fourth quarter of 2024 was €1.3 million, which excludes €0.6 million of deferred rev
- Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025. Company management will host a conference call to discuss financial results that day beginning 1:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxo
- Nyxoah Reports Third Quarter Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating ResultsFDA approval on track for first quarter 2025, U.S. commercial team build out in progressCompany fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2024. Recent Financial and Operating Highlights Presented compelling DREAM data results at International
- Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations p
- Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating ResultsFDA regulatory submission complete, U.S. approval on track for end of 2024U.S. commercial launch fully funded with over €85 million in new capital raised Mont-Saint-Guibert, Belgium – August 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2024. Recent Financial and Operating Highlights Submitted final
- Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on Tuesday, August 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relatio
- Nyxoah Reports First Quarter 2024 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating ResultsAnnounced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024 Mont-Saint-Guibert, Belgium – May 14, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2024. Recent Financial and Operating Highlights Reported the DREAM U.S. pivotal study achieved co-primary endpoints on an intent-to-treat (ITT) basis and demons
- Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or
- Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary EndpointsNyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002)Reports an Oxygen Desaturation Index (ODI) responder rate of 71.3% on an intent to treat (ITT) basis (p<0.001)Median 12-month AHI reduction of 70.8% Mont-Saint-Guibert, Belgium – March 19, 2024, 9:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary en
- Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsNyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsExpect to report DREAM U.S. pivotal study efficacy and safety data by early AprilAchieved record quarterly sales of €1.8 million Mont-Saint-Guibert, Belgium – March 5, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and financial year 2023. Recent Financial and Operating Highlights Filed the third out of four modules in the U.S. modular PMA submission.Ac
- Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Invest
- Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023. Preliminary, Unaudited Fourth Quarter and Full Year 2023 Results Revenue for the fourth quarter of 2023 is anticipated to be approximately €1.8 million, a 40% increase over the fourth quarter of 2022 and an 87% increase over the thir
- Nyxoah Reports Third Quarter 2023 Financial and Operating ResultsNyxoah Reports Third Quarter 2023 Financial and Operating ResultsPartners with ResMed Germany to increase OSA awareness and therapy penetration Mont-Saint-Guibert, Belgium – November 8, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the third quarter of 2023. Recent Financial and Operating Highlights Filed the third module in the modular PMA submission.Accelerated U.S. pre-commercialization efforts, focused on market access around CPT coding.Initiated a commercia
- Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023 Mont-Saint-Guibert, Belgium – October 26, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2023 on Wednesday, November 8, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoa
- Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results Mont-Saint-Guibert, Belgium – August 8, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2023. Recent Financial and Operating Highlights Presented 12-month efficacy data1 on the first 34 DREAM patients and safety data on all DREAM patients at SLEEP 2023, demonstrating a 65% AHI responder rate,
- Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023 Mont-Saint-Guibert, Belgium – July 27, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter of 2023 on Tuesday, August 8, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page
- Nyxoah Reports First Quarter 2023 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter 2023 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 16, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023. Recent Financial and Operating Highlights Completed all 115 implants in the DREAM U.S. pivotal trial, with 12-month data expected in the first quarter of 2024. Initiated the modular PMA submission with the filing of the first module. Submitted 12-month
- Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023 Mont-Saint-Guibert, Belgium – May 1, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter of 2023 on Tuesday, May 16, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. Investors interested in listening to the conference call may do so by registerin
- Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsCompleted all 115 implants in the DREAM U.S. pivotal study Mont-Saint-Guibert, Belgium – March 22, 2023 09:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year 2022. Recent Financial and Operating Highlights Completed all 115 implants in the DREAM U.S. pivotal trial, with 12-month data expected early next year.Filed
- Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023 Mont-Saint-Guibert, Belgium – March 8, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. Investors interested in listening to the conference call may d
- Nyxoah Reports Third Quarter 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Third Quarter 2022 Financial and Operating Results DREAM US pivotal 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium – November 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the quarter ended September 30, 2022. Third Quarter 2022 Financial and Operating Highlights Completed 110 of 115 implants in the DREAM U.S. pivotal trial to date, with 12-month clinical data expected in
- Nyxoah to Release Third Quarter Financial Results on November 8, 2022Nyxoah to Release Third Quarter Financial Results on November 8, 2022 Mont-Saint-Guibert, Belgium – October 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2022 on Tuesday, November 8, 2022, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. Investors interested in listening to the conference call may do so by
- Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results DREAM enrollment complete, 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium – August 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2022. Second Quarter 2022 Financial and Operating Highlights Completed enrollment in DREAM U.S. pivotal trial; expect 12-month clinical data in the fall of 202
- Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022 Mont-Saint-Guibert, Belgium – July 19, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half of 2022 on Monday, August 8, 2022, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. Investors interested in listening to the conference
- Nyxoah Reports First Quarter 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 10, 2022, 08:50pm CET / 2:50pm ET – Nyxoah SA (NASDAQ:NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2022. First Quarter 2022 Financial and Operating Highlights Generated revenue of €660,000 from the commercialization of Genio® in Europe, primarily in Germany, which represents year-over-year growth of more than three-and-and-half times and is more than double what was
- Nyxoah Reports First Quarter 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 9, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2022. First Quarter 2022 Financial and Operating Highlights Generated revenue of €660,000 from the commercialization of Genio® in Europe, primarily in Germany, which represents year-over-year growth of more than three-and-and-half times and is more than
- Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022 Mont-Saint-Guibert, Belgium – April 28, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter of 2022 on Monday, May 9, 2022, after the market close. Company management will host a conference call to discuss financial results on Tuesday, May 10, 2022, beginning at 2:00pm CET / 8:00am ET. Investors interested in listening to t
- Nyxoah to Release Full Year 2021 Financial Results on March 24 and Host Conference Call on March 25, 2022Nyxoah to Release Full Year 2021 Financial Results on March 24 and Host Conference Call on March 25, 2022 Mont-Saint-Guibert, Belgium – March 3, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the full year 2021 on Thursday, March 24, 2022, after the market close. Company management will host a conference call to discuss financial results on Friday, March 25, 2022, beginning at 2:00pm CET / 8:00am ET. Investors interested in listening to th
- Nyxoah Issues First Half 2021 Financial ResultsREGULATED INFORMATION Nyxoah Issues First Half 2021 Financial Results Mont-Saint-Guibert, Belgium – August 31, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced its unaudited condensed consolidated interim financial statements for the first half of 2021. Highlights $97.8 million Nasdaq IPO gross proceeds On track to complete US DREAM trial enrollment €355 thousand revenue generated in Europe, compared to no revenue for the six months ended June 30, 2020, driven mainly in Germany Increase
- Nyxoah to Release First Half 2021 Financial Results on August 31 and Host Earnings Conference Call on September 1, 2021Mont-Saint-Guibert, Belgium. - August 11, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it will release financial results for the first half of 2021 on Tuesday, August 31, 2021, after the US markets close. Company management will host a conference call to discuss financial results on Wednesday, September 1, 2021, beginning at 3:00 p.m. CET / 9:00 a.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 260-3718 for US, 0800 73264 for Belgium, or (929